The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

Abstract Purpose Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value ass...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hyerim Ha, Jin Hyoung Kang, Do Yeun Kim, Seung Jin Bae, Hee Yeon Lee
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2022-07-01
Edice:	BMC Health Services Research
Témata:	Values ASCO value framework ESMO-MCBS Carcinoma, renal cell Tyrosine kinase inhibitor Immune checkpoint inhibitor
On-line přístup:	https://doi.org/10.1186/s12913-022-08279-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!